CompletedNot Applicable

Prognostic Value of Estimated Plasma Volume in Pulmonary Hypertension

100 participantsStarted 2015-01-01

Plain-language summary

Assessment of the prognostic value of the estimation of plasma volume or its variation in patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) after acute right heart failure.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients with confirmed diagnosis of PAH or CTEPH, referred to the medical department of the investigators
✓. Patient with acute right heart failure defined by at least 2 of the following clinical features: worsening of peripheral oedema, development or increase of ascites, weight gain of more than 2.5 kg in 1 week preceding the visit and decline in one NYHA functional class compared to the previous stable state

What they're measuring

Survival

Timeframe: From the first visit to 1st April 2023

Recurrence of acute right heart failure

Timeframe: From the first visit to 1st April 2023

Acute right heart failure-free survival

Timeframe: From the first visit to 1st April 2023

Trial details

NCT IDNCT05861479

SponsorCentral Hospital, Nancy, France

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-01-01

View on ClinicalTrials.gov More Pulmonary Arterial Hypertension trials